Positive Preliminary Ph 1b/2 Data of Olvi-Vec in Advanced SCLC Announced
“We are encouraged by the Phase 1b trial data which suggests preliminary anti-tumor activity. Consistent reductions in all individual target lesions in participants experiencing disease control (5/7), combined with encouraging anti-tumor activity of the first evaluable participant in the most recent dose-escalation cohort, highlights the potential of systemically administered Olvi-Vec to provide meaningful clinical benefit for patients with relapsed or refractory extensive small cell lung cancer,” said Thomas Zindrick, President, CEO, and Chairman of Genelux. “These results are consistent with our previous Phase 2 results in platinum-resistant/refractory ovarian cancer and, with further investigation in our ongoing trials in relapsed/refractory lung cancer, we anticipate demonstrating the potential of Olvi-Vec as a platinum resensitizing immunotherapeutic agent across multiple types of recurrent cancers with significant unmet medical needs.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines